Invivyd, a biotechnology company specializing in antibody therapeutics, has announced the launch of a new pipeline discovery program focused on developing a monoclonal antibody (mAb) for the treatment of active measles infections and for post-exposure prophylaxis. This initiative follows multiple requests from healthcare professionals (HCPs) who are seeking new options to address measles outbreaks, which have been resurging in several regions due to declining vaccination rates and increased global travel. The proposed monoclonal antibody could serve as both a therapeutic intervention for individuals already infected with measles and as a preventive measure for those exposed to the virus, potentially reducing the severity and spread of outbreaks. If successful, this approach could accelerate efforts toward functional eradication of measles, complementing existing vaccination campaigns. The announcement underscores the ongoing need for innovative solutions in infectious disease management, particularly as measles remains a significant public health concern worldwide. The program is in the early stages of research and development, and further updates are expected as the project progresses.